Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Revenue (2016 - 2025)

Historic Revenue for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $104.3 million.

  • CorMedix's Revenue rose 81021.51% to $104.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.3 million, marking a year-over-year increase of 165094.91%. This contributed to the annual value of $43.5 million for FY2024, which is 12685580.24% up from last year.
  • Per CorMedix's latest filing, its Revenue stood at $104.3 million for Q3 2025, which was up 81021.51% from $39.7 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Revenue ranged from a high of $104.3 million in Q3 2025 and a low of -$13113.0 during Q3 2023
  • In the last 5 years, CorMedix's Revenue had a median value of $33895.0 in 2021 and averaged $12.6 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 29235.73% in 2023, then skyrocketed by 39747322.83% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Revenue stood at $56397.0 in 2021, then plummeted by 47.33% to $29702.0 in 2022, then plummeted by 144.15% to -$13113.0 in 2023, then skyrocketed by 238107.6% to $31.2 million in 2024, then skyrocketed by 234.11% to $104.3 million in 2025.
  • Its Revenue stands at $104.3 million for Q3 2025, versus $39.7 million for Q2 2025 and $39.1 million for Q1 2025.